ArQule, Inc. (ARQL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule, Inc. (ARQL)

ARQL 20.00

0.0%

Jan 16 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: former_pgs who wrote (226)	5/4/2005 3:22:44 AM
From: tuck	Read Replies (2) of 545

What are the odds that the low spend on preclinical work is a) due to ARQL having developed some inhouse capability in this area through recent hires, etc., as they expanded beyond 501, and/or b) the compound is sufficiently similar to 501 that lots of preclinical work isn't really necessary, and/or c) they want to keep trade secrets to themselves, so they're doing it in house, whether or not they have the capability to do so in what we might consider a timely fashion? Cheers, Tuck (in James Joyce mode)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next